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The aim of this study was to investigate the anti-inflammatory activities of tetramethylpyrazine (TMP) in 
the mice model of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) induced by oleic 
acid (0.15 ml/kg, intravenous (i.v.)). We report here that TMP (given at 160 mg/kg intraperitoneal (i.p.)) 
exerts potent anti-inflammatory effects in this model. After 4, 8 and 12 h, animal model reaction was 
observed and bronchoalveolar lavage fluid was obtained to measure proinflammatory cytokines (tumor 
necrosis factor α, interleukin 1β) and proteins by enzyme-linked immunosorbent assay and 
bicinchoninic acid protein assay kit, respectively. The protein expression of NF-κB in the lung was 
measured by immunohistochemistry and Western blotting. The results showed an increase in tumor 
necrosis factor α and interleukin 1β in the ALI/ARDS rat models. The activation of NF-κB was 
suppressed by TMP in the ALI/ARDS rats. The suppression of those molecules is controlled by NF-κB. 
These findings support the hypothesis that TMP inhibits the inflammatory process in the lung tissue 
through the suppression of NF-κB activation. Nevertheless, further investigations are required to 
determine the potential clinical usefulness of TMP in the adjunctive therapy for ARDS. 
 






Acute respiratory distress syndrome (ARDS) is a 
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86.2 of 100,000 person-years, a mortality of 38.5% and a 
with a high mortality rate, an age adjusted incidence of 
significant morbidity among  survivors  (Hug and   Lodish, 
2005). It remains as one of the major challenges in adult 
intensive care units (Estenssoro et al., 2002; Rocco et al., 
2001). ALI/ARDS can lead to sepsis, trauma and severe 
pneumonia, among which sepsis and in particular, 
pneumonia are the leading causes of ALI (Dreyfuss and 
Ricard, 2005). The molecular mechanisms underlying the 
inflammation include pattern recognition receptors, the 
coordinated expression of proinflammatory cytokines 
[tumor necrosis factor α (TNF-α) and interleukin 1β (IL-
1β) and adhesion molecules ICAM-1 and VCAM-1(Martin 
et al., 1992, 2000; Puneet et al., 2005)]. The presence of 
infiltrating leukocytes is the hallmark of pulmonary 
inflammation   associated   with   ALI.   The  activation   of  










endothelial and infiltrating inflammatory cells results in the 
production of injurious cytokines and chemokines and the 
disruption of the alveolar epithelial and capillary barriers 
contributes to the accumulation of protein-rich fluid in  the 
alveoli, decreasing lung compliance (Cristina et al., 
2004). 
Increased nuclear translocation of the transcription 
factor NF-κB contributes to the pathogenesis of ALI. NF-
κB is a transcriptional regulatory protein that modulates 
the expressions of immunoregulatory genes related to 
critical organ injury. NF-κB activation in the lung tissue is 
associated with cytokine and chemokine production, lung 
neutrophilia, epithelial permeability and lipid peroxidation 
(Blackwell et al., 1996; Liu et al., 1999), with increased 
expression of NF-κB–regulated proinflammatory genes, 
including TNF-α and IL-1β. Intraalveolar and intravascular 
fibrin deposition is frequently found in the setting of ALI or 
ARDS (McDonald et al., 1990; Idell et al., 1994). 
Procoagulant activity is enhanced in the lungs of patients 
with ARDS (Fuchs Buder et al., 1996). Fibrin deposits 
enhance inflammatory response by increasing vascular 
permeability, activating endothelial cells to produce 
proinflammatory cytokines and other mediators, inducing 
the accumulation of activated neutrophils and modulating 
immunoregulatory responses in the lung (Edward 
Abraham, 2000). 
Although improvements in supportive care and 
ventilatory strategies have contributed significantly to the 
decline in the mortality rate, a specific treatment is still 
lacking (Ware et al., 2000). An improved understanding of 
the pathogenesis of ALI/ARDS and a search for effective 
and specific therapies are still urgently needed, ideally 
with conventional pharmaceutical drugs. Tetramethyl-
pyrazine (TMP) is an alkaloid contained in ligustrazine, 
which has been used in traditional Chinese medicine for 
centuries. Its molecular formula is C8H12N2•HCI•2H2O 
(Figure 1). It is widely used to treat cardiovascular and 
cerebrovascular diseases and occasionally used to treat 
various causes of acute and chronic respiratory failure 
(Hang and Zhou, 2000). TMP has also been reported to 





modulation of arterial resistance, cerebral blood flow, 
platelet function, microcirculation and capillary per-
meability (Feng et al., 1988). Moreover, ligustrazine was 
reported     to    possess    a    very   broad   spectrum   of 
pharmacologic actions, such as antioxidant, anti-
inflammatory (Zheng et al., 2006), antifibrosis (Yan et al., 
1996), antitumor and immunomodulatory effects (Wei et 
al., 2004). 
Therefore, the present investigation was designed to 
evaluate its effect on ALI/ARDS. Different preclinical 
models of ALI/ARDS have been developed by utilizing 
different reagents including, but not limited to bleomycin, 
bacterial lipopolysaccharide (LPS) and oleic acid (OA) 
(Julien et al., 1986; Beilman, 1995; Hayashi et al., 2002; 
Kin and Ulrich, 2005; Zhou et al., 2002; Li et al., 2006). 
OA has been reported to induce ALI in a manner 
characteristic of acute respiratory distress syndrome 
(ARDS). In particular, structural and functional alterations 
consistent with ARDS, including severe alveolar 
attentuation and oedema, can be reproducibly attained in 
rats exposed to OA (Zhou et al., 2002). So we have 
chosen the oleic acid (OA)-induced ALI in rats as a 
model, with a hypothesis that the use of TMP may be one 
of the useful novel options for ALI/ARDS management. 
 
 
MATERIALS AND METHODS 
 
OA was from the Wuxi Chemical Co., Ltd., whereas TMP was from 
Suzhou Second Leaf Pharmaceutical Factory (batch H20040483). 
Rabbit monoclonal antibody anti–NF-κBp65, anti–glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), recombinant human TNF-α 
and IL-1β (enzyme-linked immunosorbent assay, ELISA) were 
purchased from Sigma Chemical. Horseradish peroxidase-
conjugated goat anti-rabbit IgG were purchased from Santa Cruz 
Biotechnology. Bicinchoninic acid (BCA) protein assay kit was 
purchased from Beijing BioTeke Biotechnologies, Inc. (Beijing, 
China). Electrophoresis apparatus and electric switch slot were 
from Bio-Rad. Image intensity and optical density (OD) analyses 






Male Sprague-Dawley rats (180 to 220 g) were provided by the 
Center of Laboratory Animal Science of Chongqing Medical 
University. The animals were housed in a controlled environment 
and provided with standard rodent chow and water. Animal care 
was in compliance with Chongqing regulations on the protection of 
animals used for experimental and other scientific purposes. 
 
 
Experimental groups and animal model of ALI/ARDS 
 
A total of 60 rats were randomly divided into control group (C group) 
and OA-treated, OA + saline–treated and OA + TMP–treated 
groups. The animals were anesthetized with 3.5% chloralhydrate 
and kept in the supine position with spontaneous breathing. ALI was 
induced by the intravenous (i.v.) injection of OA (dose, 0.15 ml/kg). 
The TMP treatment was administered 30 min after the OA injection 
at a dose of 160 mg/kg in 10% glucose intraperitoneal (i.p.). The 





found that a higher dose (160 mg/kg) of TMP led to pathology, only 
to improve significantly after the OA challenge. The rats in OA + 
saline treatment received an equal volume of 10% glucose. At each 
designated time point (4, 8 and 12 h after the OA challenge); five 
rats from each group were killed. 
 
 
Animal model reaction 
 
Faster breathing frequency, distressed respiration, reduced activity, 
erect hair and cyanotic lips and face were observed in the rats, 
which mean that the animal model was successful. 
 
 
Lung wet/dry weight ratio 
 
As an index of lung edema, the amount of extravascular lung water 
was calculated. The middle lobe of the right lung was excised and 
the wet weight was recorded. The lung was then placed in an 
incubator at 80°C for 24 h to obtain the dry weight. The wet/dry 




Collection and analysis of the bronchoalveolar lavage fluid 
(BALF) 
 
At the designated time points, BALF of the left lung was collected 
after tying off the right lung at the main stem bronchus. The rats 
were anesthetized by the i.p. injection of 3.5% chloralhydrate (350 
mg/kg) and then, the lavage of the left lungs were done three times 
with 4 ml normal saline at room temperature using a polyethylene 
tube inserted into the left main stem bronchus. 60 to 80% of the 4 
ml input volume was retrieved. The lavage fluid collected was 
centrifuged at 1,500 rpm for 10 min at 4°C and the supernatant was 
stored at -80°C until it was evaluated. The levels of TNF-α and IL-
1β in the BALF were detected by ELISA kits following the 
manufacturer's instructions. Protein determination was detected by 





After the lavage of the left lung, the middle lobe of the right lung 
tissue excised from each rat was fixed in 4% formalin and 






After the lavage of the left lung, the lower lobe of the right lung 
tissue excised from each rat was frozen in -80°C for 5 min. The 
fresh-frozen lung tissue sections (10 µm) were fixed in acetone for 
20 min, soaked in phosphate buffer solution (PBS) for 3 min (three 
times), soaked in 0.3% Triton X-100 for 15 min, soaked in PBS for 3 
min (three times), placed in goat serum for 20 min, incubated in NF-
κBp65 (1:50) at 4°C overnight, incubated in fluorescein 
isothiocyanate goat anti-rabbit fluorescent secondary antibodies 
(1:50) at 37°C for 2 h, viewed under an inverted fluorescence 
microscope and subjected to perturbation. 
 
 
Measurement of NF-κBp65 by Western blotting 
 
After the lavage of the left lung, the right lung tissue samples of the 
rats were immediately frozen in liquid nitrogen except the middle 
lobe. Frozen lung tissue was homogenized in lysis buffer (50 mmol/l  




Tris·HCl, pH 7.5; 100 mmol/l NaCl; 1% Triton X-100; 1 mmol/l 
EDTA; 1 mmol/l DTT; 0.1% SDS; 1× protease inhibitor cocktail) and 
protein concentration was determined using the BCA protein assay 
kit. Protein (50 µg) was solubilized in SDS sample buffer (50 mmol/l 
Tris·HCl, pH 6.8; containing 5% 2-mercaptoethanol, 2% SDS, 10% 
glycerol and 0.01% bromophenol blue), separated on 8% SDS-
PAGE and transferred onto a nitrocellulose membrane at 100 V for 
1 h. The membrane was then blocked with 5% nonfat dry milk in 
TBS containing 0.1% Tween 20 for 1 h at room temperature and 
subsequently exposed to 1 µg/ml of monoclonal antibodies anti-NF-
κBp 65 (1:1,000) and anti-GAPDH (1:5,000) overnight at 4°C. The 
next day, the membrane was incubated with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (1:2,500) for 1 h at 
37°C. Tagged proteins were detected using enhanced 
chemiluminescence assay and recorded on x-ray films. The OD 
value of the protein bands on the x-ray films were quantitated using 
Quantity One 4.31 analysis software. The relative OD value of NF-






All data were expressed as means ± SD. Statistical analyses were 
done using one-way ANOVA with the SPSS 10.0 software. The 
significant difference between the groups was assessed by 







Performance of rats after OA injection 
 
The symptoms of control rats were good and the 
respiratory rate (RR) was 40 to 50 times per minute. After 
OA injection, the RR went up to 135 to 160 times per 
minute. There was listlessness and decreased activity. 
They were significantly reduced after the administration of 




TMP reduced morphologic damage in lungs exposed 
to OA 
 
As illustrated in Figure 2, the lungs of mice exposed to 
OA showed marked inflammatory alterations charac-
terized by the thickening of the alveolocapillary 
membrane, the presence of alveolar hemorrhage, and 
the massive extravagation of monomorphonuclear and 
polymorphonuclear leukocytes into the alveolar spaces 
(Figure 2b) when compared with those of mice (Figure 
2a). In contrast, histologic damage was less pronounced 
in the TMP-treated mice and was dose dependent 
(Figures 2c, d and e). The amount of erythrocytes and 
leukocytes in the alveolar spaces was clearly reduced in 
the TMP-treated mice. According to the earlier mentioned 
data, we decided to use 160 mg/kg of TMP on follow-up 
examination. 
Representative histologic sections of the  lungs  harvested  




Table 1. RR, wet/dry weight and protein content of the BALF of the rats (n = 5). 
 
Group Time (h) RR W/D Protein (µg/µl) 
C 
4 43.2 ± 2.23 2.32 ± 0.19 0.14 ± 0.01 
8 44.60 ± 2.07 2.42 ± 0.83 0.15 ± 0.01 
12 46.20 ± 1.79 2.45 ± 0.19 0.14 ± 0.02 
     
OA 
4 142.8 ± 7.53*
▲
 6.80 ± 0.31*
▲
 0.54 ± 0.03*
▲
 
8 133.2 ± 3.11* 6.26 ± 0.21* 0.52 ± 0.04* 
12 131.2 ± 1.92* 6.04 ± 0.27* 0.50 ± 0.05* 
     
OA + saline 
4 138.8 ± 5.40* 6.70 ± 0.31* 0.55 ± 0.03* 
8 134.0 ± 3.67* 6.44 ± 0.31* 0.51 ± 0.02* 
12 130.8 ± 2.77* 6.08 ± 0.49* 0.51 ± 0.03* 
     
OA + TMP 
4 97.8 ± 1.78∆ 5.23 ± 0.14∆ 0.38 ± 0.43∆ 
8 93.8 ± 2.39 4.26 ± 0.21 0.30 ± 0.02 
12 88..2 ± 1.30* 4.16 ± 0.11* 0.29 ± 0.03* 
 
Notes:*, p < 0.001 versus C group; ▲, p < 0.05 versus OA group at 8 and 12 h; , p < 0.05 versus OA + 
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at 4 h (control; A); after the intratracheal instillation of OA 
(B), 40 mg/kg TMP (C), 80 mg/kg TMP (D) and 160 
mg/kg TMP (E); and after the challenge with OA at 4 h 
(D) and 12 h (F). The morphologic alterations induced by 
(LPS) were reduced by TMP treatment. Pictures are 
representative of n = 5 mice per treatment group. Original 
magnification, × 200. 
Wet/dry weight ratio and protein content in BALF 
 
Compared with the normal groups, RR increased 
significantly in the OA groups (p < 0.05). The indicators 
all decreased in the OA + TMP–treated groups (Table 1). 
A hallmark of ARDS is the development of high 
permeability edema, characterized by high protein content  









4 h          8 h         12 h                                       4 h           8 h          12 h  
 
Figure 3. Concentrations of proinflammatory cytokines in the BALF. Cytokines were measured in the BALF obtained at 4, 8 and 12 h after the 
i.v. instillation of OA. Mice receiving LPS were treated with TMP. The concentrations of TNF-α (A) and IL-1β (B) were detected by ELISA. p 
< 0.001 versus C group; *p < 0.05 versus OA group at 8 and 12 h; p < 0.05 versus OA + saline group; ▲p < 0.05 versus OA + TMP group 




content in the edema fluid. Such abnormalities were 
noted in the lungs of the mice exposed to OA. The protein 
concentration in the BALF from the control mice had 
increased from 0.14 ± 0.01 µg/µl (4 h) to 0.54 ± 0.03 
µg/µl (4 h), 0.50 ± 0.04 µg/µl (8 h) and 0.50 ± 0.05 µg/µl 
(12 h) when the mice were challenged with OA (Table 1). 
Respectively, the concentration of protein in the BALF 
was significantly lower in the OA-treated mice that 
received TMP. The most obvious time point was at 12 h 
(p < 0.05; Table 1). 
 
 
Effect of TMP on the expression of proinflammatory 
TNF-α and IL-1β in BALF 
 
A substantial increase in TNF-α and IL-1β production was 
found in the BALF (Figure 3a and b, respectively) 
collected from rats at 4, 8, and 12 h and peaked at 4 h 
after OA administration. In contrast, the levels of these 
proinflammatory cytokines were significantly lower in the 
OA-treated mice treated with TMP, which peaked at 12 h 
after OA administration. 
 
 
Immunohistochemistry for the activation of NF-κBp65 
 
Immunohistochemical analysis was carried out for in situ 
visualization and it was very clear from the immuno-
histochemical staining that NF-κBp65 expression. 
Nuclear localization of NF-κBp65 was observed in OA 
group, positive cells of the C group were less than those 
of the OA group. A complete absence of NF-κBp65 
expression was observed in OA group. However, positive 
cells decrease after TMP administration (Figure 4). The 
quantification of staining intensity was showed in Figure 5. 
Effects of TMP on the activation of NF-κB p65  
 
The rats in OA and OA + slaine saline groups expressed 
higher NF-κB p65 than the normal control rats (p < 0.05; 
Figure 6) at 4, 8 and 12 h, which peaked at 4 h after OA 
administration. TMP significantly suppressed NF-κBp65 
protein at 4, 8 and 12 h, which peaked at 12 h after TMP 
administration (p < 0.05; Figure 6). The relative OD value 






ARDS is characterized by the development of inter-
connected inflammatory cascades, with proinflammatory 
cytokines playing a central role in the initiation and 
propagation of the inflammatory response leading to lung 
injury. TNF-α and IL-1β are considered pivotal mediators 
of lung inflammation in ARDS (Agouridakis and Meduri, 
2002). TNF-α and IL-1β released by alveolar 
macrophages stimulate target cells (notably epithelial and 
endothelial cells) to produce additional mediators, 
thereby amplifying the initial inflammatory response. High 
TNF-α and IL-1β concentrations are found in the BALF of 
ARDS patients, particularly those who succumb to the 
disorder. 
This study showed that TMP exerted potent anti-
inflammatory and immunomodulatory effects in the lungs 
exposed to OA. The symptoms of rats improved in the 
TMP-treated. The respiratory rate became smooth and 
the cyanosis of skin and mucous membrane improved. 
TMP reduced the infiltration of activated poly-
morphonuclear neutrophils in the airways and  decreased  
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Figure 4. Immunohistochemistry for NF-κBp65 with positive staining (arrows) mainly localized along the 
alveolar nuclei of the rats. At 4 h (B) after OA administration, the intensity of the positive staining for NF-
κBp65 was significantly more than that of the C (A), 8-h (C) and 12-h (D) groups. It was reduced in the 
lungs of TMP-treated mice after TMP administration at 4 h (E), 8 h (F) and 12 h (G). This is representative 





      4 h                      8 h                    12 h  
 
Figure 5. Quantification of staining Intensity. For intensity measurements, each image 
was converted to grayscale before analysis using Olympus Micro Suite Five image 
processing software. , p < 0.05 versus C group; *, p < 0.05 versus OA group at 8 and 
12 h; , p < 0.05 versus OA + saline group; ▲, p < 0.05 versus OA + TMP group at 4 
and 8 h. 















      4 h               8 h             12 h  
 
Figure 7. Relative OD value of NF-κBp65 Western blot in each group. , p < 
0.05 versus the C group; *, p < 0.05 versus OA group at 8 and 12 h; , p < 0.05 




pulmonary edema. The concentration of protein in the 
BALF was significantly lower in the OA-treated mice that 
received TMP. The most obvious time point was at 12 h 
(Table 1), with improved lung morphology (Figure 2) and 
downregulated expression of proinflammatory cytokines 
and chemokines TNF-α and IL-1β (Figures 3a and b). 
What then is the mechanism by which TMP protects 
against inflammatory injury? A variety of findings support 
a role in the activation of the transcription factor NF-κB in 
the regulation of the inflammatory responses (Baldwin, 
2004; Demoule et al., 2006). NF-κB is a general term 
used to describe a number of dimeric combinations of 
members of the Rel family of gene regulatory proteins 
that possess transcription-activating properties (Ghosh et 
al., 1998). In the NF-κB pathway, the presence of 
inhibitory factor κB (IκB) and the IκB/NF-κB interactions 
prevent the nuclear translocation of NF-κB by masking 
the nuclear localization sequences of the NF-κB dimers. 
The degradation of IκB leads to the activation of NF-κB, 
which is defined as the translocation of the NF-κB 
complex from the cytoplasm to the nucleus. Once in the 
nucleus, NF-κB binds specific promoter elements of the 
DNA and induces the transcription of relevant genes. The 
results of this study show that TMP inhibits, in particular, 
the DNA binding of the NF-κB dimer containing the p65 
subunit, a complex that is transcriptionally active in 
comparison with the p50 homodimer (Cuzzocrea et al., 
2004). 
The present study has shown that there was a 
significant increase in TNF-α and IL-1β, which  peaked  at  




4 h after OA administration (Figures 3a and b). Mean-
while, there was a significant increase in NF-κBp65, 
which peaked at 4 h  after  OA  administration  (Figure 4). 
TNF-α and IL-1β were significantly reduced by TMP 
(Figure 3). We showed that TMP attenuates TNF-α and 
IL-1β expression in the OA-treated lungs, probably 
because of its blockage of NF-κB. Therefore, the exact 
mechanisms by which TMP suppresses NF-κB activation 
in inflammation remain to be further elucidated. Its 
antioxidant property should be responsible for the ability 
to inhibit NF-κB. We further showed that the dose of NF-
κB used (160 mg/kg i.p.) is sufficient to inhibit the 
activation of NF-κB in rats. 
In conclusion, our results indicate that in the OA-
induced ALI/ARDS model, TMP has strong anti-
inflammatory properties, resulting in a reduced (a) 
respiratory rate; (b) pulmonary edema; (c) concentration 
of protein in the BALF; (d) lung tissue injury; (e) TNF-α 
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